scripps florida scientists find ‘functional cure’ for hiv

1
JUPITER — Computers have changed dramatically, but tips for buying? Not so much All owners usually must OK converting common elements to private Palm Beach County’s largest local bank becomes part of Treasure Coast’s largest bank Is an energy-efficient fridge worth the money? 7 last-minute ways to save money on your next vacation Scripps Florida scientists find ‘functional cure’ for HIV BUSINESS By Jeff Ostrowski - Palm Beach Post Staff Writer Posted: 2:37 p.m. Thursday, November 02, 2017 In findings that could point to a better treatment for HIV infections, Scripps Florida scientists say they’ve found a new way to manage the virus. Scripps Associate Professor Susana Valente says she successfully tested a drug that promises a “functional cure” for HIV: The infection isn’t gone, but the virus lies dormant. RELATED: Federal grants to Florida scientists top $600 million, breaking record The results of a study led by Valente were published in October in the journal Cell Reports. Valente and researchers from Scripps Florida, the University of North Carolina and Walter Reed Army Institute of Research used a natural compound known as didehydro-Cortistatin A, or dCA. It stops the spread of HIV by inhibiting the protein Tat. “It is really the proof of concept for a functional cure,” Valente said. HIV, the precursor to AIDS, no longer is the death sentence it was in the 1980s. Still, HIV remains a chronic disease that requires regular medication. Patients take so-called cocktails of antiretroviral drugs that keep the infection in check but don’t kill the virus. will rebound,” Valente said. Her research found that dCA can suppress HIV to the point that even if a patient stops taking medication, the HIV infection won’t come back immediately. In half of mice treated with dCA, HIV levels disappeared for 16 days after all antiretroviral drugs were stopped, researchers said. Researchers tested dCA both in cells of humans with HIV and in mice infected with HIV. In another apparent benefit of dCA, Valente said the compound also can stop the neurological deterioration caused by HIV. Even while taking medication that controls their HIV, patients can suffer motor dysfunction, speech problems and other cognitive issues. Valente, a native of Portugal who joined Scripps Florida in 2009, has spent years investigating dCA. She won grants from the National Institutes of Health to support her work. Valente champions an approach to HIV known as “block and lock.” The strategy aims to block the reactivation of the virus in cells, and leave HIV dormant. The dominant approach toward HIV research in recent years has been “shock and kill.” Scientists look for ways to eradicate the virus rather than simply manage it, and that plan of attack has won much of the research funding. “Everybody was going berserk for shock and kill,” Valente said. Marcella Flores, associate director of research at amfAR, an AIDS research foundation in New York, called the results of Valente’s research both “very exciting” and a vindication for Valente’s approach to vanquishing HIV. “It is the first study to show the strength of block and lock,” Flores said. She noted that sending HIV into remission isn’t as satisfying as killing it altogether. Patients with dormant HIV still would have to visit physicians regularly and still would carry the stigma of HIV. But Flores said she’s not taking sides in the shock and kill vs. block and lock debate. “I am agnostic about what cure is going to be the winner in the end,” Flores said. “There’s merit to both.” Valente, for her part, hopes a successful experiment gives momentum to her approach. Reflecting the long-term nature of basic research, Valente’s HIV treatment is years away from being marketed to patients. “Now there’s a million questions,” she said. Among them: For how long does dCA work? Might the virus rebound someday? Would a big pharma partner be willing to test the treatment in humans? “We’ve found this works, so now we need to push it into the clinic,” Valente said. “That’s pharma’s job.” An estimated 1.1 million people in the United States were living with HIV at the end of 2014, and nearly 37 million people worldwide were infected at the end of 2016, according to the U.S. Centers for Disease Control. In the United States, 6,721 people died from HIV and AIDS in 2014, the CDC says. Globally, about a million people a year die of AIDS-related diseases. “HIV is still in epidemic proportions in certain populations,” Flores said. Reader Comments Next Up in More Stories 74° SUBSCRIBE as low as 99¢ 15 Scripps Florida researcher Susana Valente is working on “a functional cure” for HIV at her lab in Jupiter on November 1, 2017. (Richard Graulich / The Palm Beach Post) JEFF OSTROWSKI About the Author 15 © 2017 Cox Media Group. By using this website, you accept the terms of our Visitor Agreement and Privacy Policy, and understand your options regarding Ad Choices . Learn about careers at Cox Media Group NEWS MARKETPLACE AFFILIATES ABOUT US SUBSCRIBE

Upload: others

Post on 27-Apr-2022

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Scripps Florida scientists find ‘functional cure’ for HIV

JUPITER —

Computers have changed dramatically, buttips for buying? Not so much

All owners usually must OK convertingcommon elements to private

Palm Beach County’s largestlocal bank becomes part ofTreasure Coast’s largest bank

Is an energy-efficient fridgeworth the money?

7 last-minute ways to savemoney on your next vacation

Scripps Florida scientists find‘functional cure’ for HIV

BUSINESS By Jeff Ostrowski - Palm Beach Post Staff Writer

� �

Posted: 2:37 p.m. Thursday, November 02, 2017

In findings that could point to a bettertreatment for HIV infections, Scripps Florida scientistssay they’ve found a new way to manage the virus.

Scripps Associate Professor Susana Valente saysshe successfully tested a drug that promises a“functional cure” for HIV: The infection isn’t gone, butthe virus lies dormant.

RELATED: Federal grants to Florida scientists top$600 million, breaking record

The results of a study led by Valente were publishedin October in the journal Cell Reports. Valente andresearchers from Scripps Florida, the University ofNorth Carolina and Walter Reed Army Institute ofResearch used a natural compound known asdidehydro-Cortistatin A, or dCA. It stops the spread ofHIV by inhibiting the protein Tat.

“It is really the proof of concept for a functional cure,”Valente said.

HIV, the precursor to AIDS, no longer is the deathsentence it was in the 1980s. Still, HIV remains achronic disease that requires regular medication.Patients take so-called cocktails of antiretroviral drugsthat keep the infection in check but don’t kill the virus.

“As soon as somebody stops treatment, these cellswill rebound,” Valente said.

Her research found that dCA can suppress HIV to thepoint that even if a patient stops taking medication,the HIV infection won’t come back immediately. Inhalf of mice treated with dCA, HIV levels disappearedfor 16 days after all antiretroviral drugs were stopped,researchers said.

Researchers tested dCA both in cells of humans withHIV and in mice infected with HIV.

In another apparent benefit of dCA, Valente said thecompound also can stop the neurologicaldeterioration caused by HIV. Even while takingmedication that controls their HIV, patients can suffermotor dysfunction, speech problems and othercognitive issues.

Valente, a native of Portugal who joined ScrippsFlorida in 2009, has spent years investigating dCA.She won grants from the National Institutes of Healthto support her work.

Valente champions an approach to HIV known as“block and lock.” The strategy aims to block thereactivation of the virus in cells, and leave HIVdormant.

The dominant approach toward HIV research inrecent years has been “shock and kill.” Scientists lookfor ways to eradicate the virus rather than simplymanage it, and that plan of attack has won much ofthe research funding.

“Everybody was going berserk for shock and kill,”Valente said.

Marcella Flores, associate director of research atamfAR, an AIDS research foundation in New York,called the results of Valente’s research both “veryexciting” and a vindication for Valente’s approach tovanquishing HIV.

“It is the first study to show the strength of block andlock,” Flores said.

She noted that sending HIV into remission isn’t assatisfying as killing it altogether. Patients withdormant HIV still would have to visit physiciansregularly and still would carry the stigma of HIV. ButFlores said she’s not taking sides in the shock and killvs. block and lock debate.

“I am agnostic about what cure is going to be thewinner in the end,” Flores said. “There’s merit toboth.”

Valente, for her part, hopes a successful experimentgives momentum to her approach. Reflecting thelong-term nature of basic research, Valente’s HIVtreatment is years away from being marketed topatients.

“Now there’s a million questions,” she said.

Among them: For how long does dCA work? Mightthe virus rebound someday? Would a big pharmapartner be willing to test the treatment in humans?

“We’ve found this works, so now we need to push itinto the clinic,” Valente said. “That’s pharma’s job.”

An estimated 1.1 million people in the United Stateswere living with HIV at the end of 2014, and nearly 37million people worldwide were infected at the end of2016, according to the U.S. Centers for DiseaseControl.

In the United States, 6,721 people died from HIV andAIDS in 2014, the CDC says. Globally, about a millionpeople a year die of AIDS-related diseases.

“HIV is still in epidemic proportions in certainpopulations,” Flores said.

Reader Comments

Next Up in

More Stories

74° �SUBSCRIBEas low as 99¢ �

15

Scripps Florida researcher Susana Valente is working on “afunctional cure” for HIV at her lab in Jupiter on November 1, 2017.(Richard Graulich / The Palm Beach Post)

JEFF OSTROWSKI

About the Author

15

© 2017 Cox Media Group. By using this website, youaccept the terms of our Visitor Agreement and Privacy

Policy, and understand your options regarding Ad Choices . Learn about careers at Cox Media Group

NEWS

MARKETPLACE

AFFILIATES

ABOUT US

SUBSCRIBE

04/11/2017, 14)24Page 1 of 1